Identification of a human SOCS1 polymorphism that predicts rheumatoid arthritis severity
| Autor: | Pilar de Lucas, Amalia Lamana, Rosa P. Gomariz, Ana Márquez, Ricardo Villares, Isidoro González-Álvaro, Mario Mellado, Edward M Vital, Robin Maxime, Ana Triguero-Martinez, Ana M. Ortiz, Frederique Ponchel, Javier Martín, Nuria Andrés, Paul Emery, Iria V. Seoane, Carmen Martínez |
|---|---|
| Přispěvatelé: | Ministerio de Economía y Competitividad (España), European Commission, Instituto de Salud Carlos III, Consejo Superior de Investigaciones Científicas (España) |
| Rok vydání: | 2020 |
| Předmět: |
rheumatoid arthritis
lcsh:Immunologic diseases. Allergy 0301 basic medicine Oncology Bioquímica medicine.medical_specialty Exacerbation medicine.medical_treatment Immunology Arthritis Single-nucleotide polymorphism 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Immunology and Allergy Suppressor of cytokine signaling 1 business.industry biomarkers medicine.disease Reumatología cytokines 3. Good health 030104 developmental biology Cytokine inflammation Rheumatoid arthritis Rituximab lcsh:RC581-607 Cell activation business disease activity 030215 immunology medicine.drug |
| Zdroj: | E-Prints Complutense. Archivo Institucional de la UCM instname Frontiers in Immunology, Vol 11 (2020) E-Prints Complutense: Archivo Institucional de la UCM Universidad Complutense de Madrid Digital.CSIC. Repositorio Institucional del CSIC |
| ISSN: | 1664-3224 |
| Popis: | Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by an autoimmune response in the joints and an exacerbation of cytokine responses. A minority of patients with RA experience spontaneous remission, but most will show moderate/high disease activity, with aggressive joint damage and multiple systemic manifestations. There is thus is a great need to identify prognostic biomarkers for disease risk to improve diagnosis and prognosis, and to inform on the most appropriate therapy. Here we focused on suppressor of cytokine signaling 1 (SOCS1), a physiological negative regulator of cytokines that modulates cell activation. Using four independent cohorts of patients with arthritis, we characterized the correlation between SOCS1 mRNA levels and clinical outcome. We found a significant inverse correlation between SOCS1 mRNA expression and disease activity throughout the follow-up of patients with RA. Lower baseline SOCS1 levels were associated with poorer disease control in response to methotrexate and other conventional synthetic disease-modifying anti-rheumatic drugs in early arthritis, and to rituximab in established (active) RA. Moreover, we identified several single nucleotide polymorphisms in the SOCS1 gene that correlated with SOCS1 mRNA expression, and that might identify those patients with early arthritis that fulfill RA classification criteria. One of them, rs4780355, is in linkage disequilibrium with a microsatellite (TTTTC), mapped 0.9 kb downstream of the SNP, and correlated with reduced SOCS1 expression in vitro. Overall, our data support the association between SOCS1 expression and disease progression, disease severity and response to treatment in RA. These observations underlie the relevance of SOCS1 mRNA levels for stratifying patients prognostically and guiding therapeutic decisions. This work was supported in part by grants from the Spanish Ministry of Economy and Competitiveness/FEDER (SAF 2017-82940-R; PI14/00442, PI17/00027, PI18/00371), the RETICS Program of the Instituto de Salud Carlos III (RIER: RD16/0012/0006; RD16/0012/0008; RD16/0012/0011; RD16/0012/0013) and the European Union (Masterswitch FP7-Health-2007-B-223404). We also obtained funds from the Spanish Natonal Research Council for open access publication fees |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|